imatinib mesylate has been researched along with Cancer of the Fallopian Tube in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aghajanian, C; Hensley, ML; Iasonos, A; Juretzka, M; Konner, J; Leitao, M; Park, K; Sabbatini, P; Soslow, R; Tew, W | 1 |
| Branham, D; Broaddus, RR; Coleman, RL; Gershenson, DM; Levenback, CF; Noguera, IR; Ramirez, PT; Sood, AK; Sun, CC | 1 |
| Bodurka, DC; Broaddus, RR; Burke, TW; Coleman, RL; Gershenson, DM; Kavanagh, JJ; Levenback, CF; Wolf, JK | 1 |
3 trial(s) available for imatinib mesylate and Cancer of the Fallopian Tube
| Article | Year |
|---|---|
A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission.
Topics: Administration, Oral; Adult; Aged; Benzamides; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2008 |
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Taxoids | 2012 |
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Piperazines; Pyrimidines; Taxoids | 2006 |